ELTOPRAZINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H16N2O2.ClH
Molecular Weight	256.729
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.C1CN(CCN1)C2=C3OCCOC3=CC=C2

InChI

InChIKey=JFSOSUNPIXJCIX-UHFFFAOYSA-N

InChI=1S/C12H16N2O2.ClH/c1-2-10(14-6-4-13-5-7-14)12-11(3-1)15-8-9-16-12;/h1-3,13H,4-9H2;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C12H16N2O2
Molecular Weight	220.2676
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1982626 | https://clinicaltrials.gov/ct2/show/NCT02439125 | https://clinicaltrials.gov/ct2/show/NCT01266174

Eltoprazine, a 5-HT1A/B receptor partial agonist, was created by Duphar in the 1980s (as DU-28853) and was subsequently developed by Solvay to treat pathological aggression. This drug is in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), Alzheimer's aggression and adult attention deficit hyperactivity disorder (adult ADHD). In addition, was shown, that the drug could be useful for normalizing prefrontal cognitive abilities, reducing aggression and impulsivity, and improving cognitive function in schizophrenia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
5-hydroxytryptamine receptor 1A 54 Target ID: P08908 Gene ID: 3350.0 Gene Symbol: HTR1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1982626	Partial Agonist 290		40.0 nM [Ki]
5-hydroxytryptamine receptor 1B 21 Target ID: P28222 Gene ID: 3351.0 Gene Symbol: HTR1B Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1982626	Partial Agonist 290		52.0 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Drug-induced dyskinesia 4 Sources: https://clinicaltrials.gov/ct2/show/NCT02439125	Primary	Phase II 1132	Unknown Approved Use Unknown
Schizophrenia 298 Sources: https://clinicaltrials.gov/ct2/show/NCT01266174	Primary	Phase II 1132	Unknown Approved Use Unknown
Attention deficit hyperactivity disorder 68 Sources: https://www.amarantus.com/news/press-releases/detail/1644/amarantus-provides-program-update-on-phase-2b-eltoprazine	Primary	Phase II 1132	Unknown Approved Use Unknown
Alzheimer's aggression 2 Sources: https://www.amarantus.com/news/press-releases/detail/2033/amarantus-announces-positive-phase-2-data-for-eltoprazine	Primary	Phase II 1132	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
62.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1761079	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		ELTOPRAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
746 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1761079	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		ELTOPRAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1761079	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		ELTOPRAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
9.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2288834	8 mg single, intravenous dose: 8 mg route of administration: Intravenous experiment type: SINGLE co-administered:		ELTOPRAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

eltoprazine HCl 2.5; 5 or 7.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks

Route of Administration: Oral

In Vitro Use Guide

There was localized and characterized the binding sites of [3H]eltoprazine in the rat brain. The binding of [3H]eltoprazine to whole tissue sections was saturable and revealed an apparent dissociation constant (Kd) of 11 nM. Autoradiographic studies demonstrated a widespread distribution of [3H]eltoprazine binding sites throughout the brain. Specific [3H]eltoprazine binding was completely displaced by 5-HT; conversely, unlabeled eltoprazine reduced [3H]5-HT binding to the levels of non-specific binding. The pharmacological and anatomical data indicate that eltoprazine binds to 5-HT1A, 5-HT1B and to a lesser extent to 5-HT1C binding sites in the rat brain.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:40:32 GMT 2023` Edited by `admin` on `Fri Dec 15 15:40:32 GMT 2023`
Record UNII	5275JY4PKD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ELTOPRAZINE HYDROCHLORIDE

Common Name

English

ELTOPRAZINE HYDROCHLORIDE [MI]

Common Name

English

DU-28893

Code

English

DU-28853

Code

English

PIPERAZINE, 1-(2,3-DIHYDRO-1,4-BENZODIOXIN-5-YL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

504215